Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Disci/Rhus toxicodendron comp · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | ACTIVE_COMPARATOR | Disci/Rhus toxicodendron comp.® |
| 2 | PLACEBO_COMPARATOR | placebo solution |
| 3 | NO_INTERVENTION | waiting list group |
| Name | Type | Description |
|---|---|---|
| Disci/Rhus toxicodendron comp.® | DRUG | s.c. application 10 ml (1 ampul) in 5 to 10 parts on different back pain sites verum group 12 treatments: 8 in the first 4 weeks and 4 in the next 4 weeks |
| placebo solution | DRUG | s.c. application 10 ml (1 ampul) in 5 to 10 parts on different back pain sites 12 treatments: 8 in the first 4 weeks and 4 in the next 4 weeks |
Inclusion Criteria: * Male and female patients, 30 to 75 years * Willingness of following the study protocol * Clinical diagnosis of chronic low back pain * Low back pain since at least 3 months * Average pain intensity of at least 40 mm on VAS (0-100 mm) in the last 7 days * In the last 4 weeks on...
Top 20 of 25 competitors
Disci/Rhus toxicodendron comp is an investigational small molecule being studied for the treatment of chronic low back pain. It is currently in Phase 3 clinical development and has not been approved by the FDA.
Disci/Rhus toxicodendron comp is being developed by Pulmonx Corporation, a company traded on the NASDAQ under the ticker symbol LUNG.
Disci/Rhus toxicodendron comp is in Phase 3 clinical development. It is an investigational drug and has not been approved by the FDA for any use.
Disci/Rhus toxicodendron comp has one completed Phase 3 clinical trial, NCT00567736, which evaluated its efficacy in patients with chronic low back pain. The trial enrolled 150 participants in Germany and was randomized, double-blind, and placebo-controlled.
Disci/Rhus toxicodendron comp is a combination product that includes Rhus toxicodendron as one of its components. The full name reflects the combination of Disci and Rhus toxicodendron, and it is being studied specifically for chronic low back pain.